Transcutaneous auricular vagus nerve stimulation in anesthetized mice induces antidepressant effects by activating dopaminergic neurons in the ventral tegmental area Authors: Tae-Yong Choi, Jeongseop Kim, Ja Wook Koo Published: 2024 ABSTRACT AbstractDepression, a prevalent neuropsychiatric disorder, involves the dysregulation of neurotransmitters such as dopamine (DA). The restoration of DA balance is a pivotal therapeutic target for this condition. Recent studies have indicated that both antidepressant medications and non-pharmacological treatments, such as transcutaneous auricular vagus nerve stimulation (taVNS), can promote recovery from depressive symptoms. Despite the promise of taVNS as a non-invasive depression therapy, its precise mechanism remains unclear. We hypothesized that taVNS exerts antidepressant effects by modulating the DAergic system. To investigate this, we conducted experiments demonstrating that taVNS in anesthetized mice reduced depressive-like behaviors. However, this effect was abolished when DA neurons in the ventral tegmental area (VTADA) were inhibited. Additionally, taVNS in anesthetized mice enhanced VTADA activity, providing further evidence to support its antidepressant effects. Overall, our findings suggest that taVNS alleviates depression by augmenting VTADA activity, thereby contributing to a more comprehensive understanding of its therapeutic mechanisms.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13041-024-01162-x.Keywords: Depression, Transcutaneous auricular vagus nerve stimulation, Antidepressant, Ventral tegmental area, Dopamine, Chronic social defeat stress, Forced swim test, Fiber photometry Introduction Depression, or major depressive disorder (MDD), is a prevalent and severe neuropsychiatric disease characterized by persistent low mood and diminished interest or pleasure in activities. Although numerous factors can contribute to depression, its principal determinants remain elusive. Emerging evidence has indicated that the dysregulation of neurotransmitters, notably dopamine (DA), particularly within brain regions governing emotions, cognition, sleep, and appetite, plays a pivotal role in its etiology [1]. As such, restoring the balance in brain chemistry may alleviate depression. It has been widely recognized that the activity of DA neurons in the ventral tegmental area (VTADA) and DA release to various brain regions regulate mood-related behaviors. Indeed, research has shown that stress or aversive stimuli suppress VTADA activity [2], while the optogenetic inhibition of VTADA leads to a depressive-like phenotype. Conversely, phasic photoactivation of VTADA has been shown to mitigate chronic stress-induced depressive symptoms [3]. Overall, these findings underscore the importance of regulating VTADA as a primary therapeutic approach for depression. Numerous antidepressant medications, including dopamine agonists, dopamine reuptake inhibitors, and norepinephrine and dopamine reuptake inhibitors, as well as non-pharmacological therapies, such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, and vagus nerve stimulation (VNS), have all been employed in the treatment of depression, to regulate the DAergic system [4]. In particular, non-invasive VNS modalities, such as transcutaneous auricular VNS (taVNS), are increasingly being used to treat depression owing to their multifaceted advantages [5]. However, the precise mechanism by which taVNS mitigates depression remains unclear. Results We hypothesized that taVNS exerts its antidepressant effects by activating VTADA activity. Initially, we investigated whether taVNS induced this effect through conduction of the forced swim test (FST), a standard rodent behavioral test commonly used to assess the efficacy of antidepressant drugs or treatments in eliciting or preventing depressive-like states, 20 min after sham (i.e., off-site stimulation) or taVNS intervention in anesthetized mice (Fig. 1A, B) [6]. As a result, taVNS, but not sham treatment, in anesthetized mice led to a reduction in immobility time during the FST, indicating its antidepressant effect (Fig. 1C). taVNS induces antidepressant effects by increasing VTADA activity. A The FST procedure without (i.e., off-site stimulation or sham control) or with taVNS intervention. B A representative image of a mouse treated with taVNS, followed by the cymba and cavum concha of the vagus innervation area in the ear. C Immobility time during the FST. Animals were treated with or without taVNS. Values are shown as the mean ± standard error of the mean (SEM) (n = 6 mice per group; Student’s t-test [unpaired, two-tailed]; *p < 0.05). D Schematic diagram depicting the experimental procedure for CSDS and social interaction test (SIT) with or without taVNS. E taVNS significantly reversed CSDS-induced social avoidance. (n = 5 mice per group; Student’s t-test [paired, two-tailed]; ns, not significant; *p < 0.05). F Schematic illustration of viral injection to inhibit VTADA. G Representative images of brain sections injected with AAV-rTH-Cre and AAV-DIO-EYFP (top) or AAV-DIO-Kir2.1-EGFP (bottom) into the VTA. DAPI, blue; EYFP (top) or Kir2.1-EGFP (bottom), green. Scale bars, 1000 μm. H Immobility time during the FST. Control and VTADA-inhibited mice were treated with or without taVNS. Values are shown as mean ± SEM (n = 6 mice per group; Two-way ANOVA with Fisher’s LSD multiple comparisons test; ns, not significant; ***p < 0.001; ****p < 0.0001). I Schematic illustration of viral injection and optic fiber implantation to measure VTADA activity using fiber photometry. J A representative image of a brain section infected with AAV-rTH-Cre and AAV-Flex-jGCaMP8f in the VTA. A fiber optic cannula was implanted above the viral injection site. DAPI, blue; jGCaMP8f, green. Scale bar, 500 μm. K Procedure for fiber photometry recordings with taVNS. L Representative Ca2+ traces from a single animal. Data are presented as the percentage change in fluorescence over the mean fluorescence (ΔF/F). Top, taVNS_OFF (before, 10 min); middle, taVNS_ON (10 min); bottom, taVNS_OFF (after, 30 min). M Peak analysis of Ca.2+ imaging traces. (n = 6 mice; repeated-measures one-way ANOVA with Tukey’s multiple comparisons test; *p < 0.05; **p < 0.01) Additionally, we explored whether taVNS could alleviate depressive symptoms induced by chronic social defeat stress (CSDS), an ethologically validated animal model of depression [7, 8]. CSDS markedly diminished social interaction with an aggressor mouse only in susceptible mice, while resilient mice were unaffected (Fig. S1). Notably, our findings revealed that taVNS treatment in an anesthetized state effectively reversed CSDS-induced social avoidance (Fig. 1D, E). These results suggest that taVNS may exert anti-stress or antidepressant effects under both normal and depressive conditions. Next, we examined whether the antidepressant effects of taVNS in anesthetized mice are mediated by VTADA activity. To investigate this, we performed the FST with or without taVNS in mice that received AAV-rTH-Cre [9] and AAV-DIO-Kir2.1-EGFP [10] into the VTA to inhibit VTADA (Fig. 1F, G). As anticipated, inhibition of VTADA resulted in increased immobility time during the FST (Fig. 1H), consistent with findings from a previous study [3]. Importantly, taVNS in an anesthetized state did not reduce immobility time in these mice (Fig. 1H). These results indicate that the antidepressant effects of taVNS are mediated through VTADA activity. Finally, we investigated whether taVNS influenced VTADA activity. To accomplish this, we measured VTADA activity via fiber photometry in mice that received AAV-rTH-Cre and AAV-Flex-jGCaMP8f [11] and implanted optic fibers into the VTA (Fig. 1I, J). Overall, we found that taVNS in anesthetized mice increased the frequency of Ca2+ transients of VTADA, suggesting an increase in the average activity of VTADA (Fig. 1K–M). Interestingly, the increased activity of VTADA induced by taVNS was further increased for 30 min following taVNS (Fig. 1K–M). These results indicate that the potentiation of VTADA activity by taVNS resulted in an antidepressant effect. Discussion The vagus nerve, also known as the tenth cranial nerve, is one of the 12 cranial nerves that emerge directly from the brain. It plays a crucial role in the parasympathetic nervous system, which regulates numerous unconscious bodily functions such as heart rate, digestion, and respiratory rate. Further, the vagus nerve has been implicated in the body’s response to stress. The activation of the vagus nerve can induce relaxation and calmness [12]. Consequently, despite the use of VNS for depression treatment, its precise mechanisms remain incompletely understood. Information from several peripheral organs is relayed to the brain, particularly to the nucleus of the solitary tract (NTS) in the brainstem. The NTS is interconnected with various brain regions responsible for synthesizing specific neurotransmitters, including the locus coeruleus, which produces norepinephrine, the dorsal raphe nucleus, which synthesizes serotonin, and the VTA, which produces DA [13]. This suggests that VNS can be used to treat various neuropsychiatric disorders, including depression, by modulating these neurotransmitter systems throughout the brain. Although previous studies have reported that invasively implanted VNS induces an antidepressant effect [14, 15] and activates VTADA [16], whether and how non-invasive taVNS elicits an antidepressant effect currently remains unclear. Invasive VNS is effective for treating various neuropsychiatric disorders and has sustained therapeutic effects. However, it carries the risks of surgery, including infection, pain, and high cost [17]. Conversely, taVNS offers a non-invasive approach without the need for surgical procedures, along with high levels of safety, ease of use, and relatively low cost [18]. Overall, our findings suggest that taVNS in anesthetized mice triggers antidepressant effects by enhancing VTADA activity. Further investigation is required to identify the specific brain regions where the heightened VTADA activity induced by taVNS results in increased DA release and whether this contributes to the antidepressant effect. Furthermore, preclinical validation in animal models of depression is essential to confirm whether taVNS is effective for clinical application based on the mechanisms we have elucidated. Supplementary Information Additional file 1. Acknowledgements We thank all members of Behavioral Neuroepigenetics Lab at Korea Brain Research Institute (KBRI) for helpful discussion. We also thank staffs in the Laboratory Animal Center at KBRI for their care of experimental animals and in the Brain Research Core Facilities at KBRI for their assistance of image acquisition. Abbreviations Adeno-associated virus Chronic social defeat stress Dopamine Forced swim test Major depressive disorder Social interaction Social interaction test Transcutaneous auricular vagus nerve stimulation Tyrosine hydroxylase Vagus nerve stimulation Ventral tegmental area Author contributions TYC and JWK designed and supervised the entire study. TYC and JK performed all experiments and data analysis. TYC wrote the manuscript. All authors edited the manuscript. Funding This research was supported by KBRI basic research program through Korea Brain Research Institute (24-BR-02-02 and 24-BR-05-04, JWK; 24-BR-02-08, JK) and by the National Research Foundation of Korea (NRF) grant (RS-2024-00358003, TYC) funded by the Korea government (Ministry of Science and ICT). Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request. Declarations Ethics approval and consent to participate All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Korea Brain Research Institute (IACUC-22-00050 and IACUC-24-00008). Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Tae-Yong Choi and Jeongseop Kim have contributed equally to this work. Contributor Information Tae-Yong Choi, Email: tychoi5667@kbri.re.kr. Ja Wook Koo, Email: jawook.koo@kbri.re.kr. References Associated Data Supplementary Materials Additional file 1. Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.